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Dear Editor,
We read with interest the article by Seck SM et al. (1) 
recently has appeared in the Journal, in which they de-
scribe the epidemiological patterns of CKD-MBD in end-
stage renal disease patients undergoing chronic hemodi-
alysis in Senegal.
First we would like to underline the interest of such 
studies made in countries with a particular situation 
with limited resources, where dialysis access is still poor 
and complementary therapies as phosphate binders, vi-
tamin D analogs or Cinacalcet are restricted or prohibi-
tive. All of these conditions make difficult to compare 
their results with those obtained in Western countries. 
Nevertheless, the reported results are not bad, with 32%, 
39% and 35% of patients in the recommended guidelines 
for calcium, phosphate and parathyroid hormone (PTH). 
In any case, there are some aspects that we would like 
to comment. As the authors mention, interpretation of 
parathormone levels in black subjects might be cautious. 
It is well known that black patients have higher parathy-
roid gland mass and circulating PTH levels than whites. 
This may predispose black patients to more severe para-
thyroid disease when renal failure develops (2). Neverthe-
less, how the correlations between PTH levels and bone 
turnover apply to black patients is less known, since 
black patients may have a relative resistance to PTH.
A major determinant of hyperparathyroidism develop-
ment, other than race, is serum phosphorus (3), in this 
line we want to add some comments. As the authors ex-
plain, all patients were dialysed with a 1.75 mmol/L cal-
cium dialysate, the question is why? KDIGO CKD–MBD 
recommendation’s state in point 4.1.3 to use a dialysate 
calcium concentration between 1.25 and 1.50 mmol/L 
(2.5 and 3.0 mEq/L) (2D) (4). I believe that practice could 
have some favorable consequences: for patients with a 
dynamic bone disease, for better control of valvular and 
peripheral vascular calcifications. Also, considering the 
importance of control of phosphorous, using les calcium 
in dialysate can allow a more liberal use of calcium salts 
that are inexpensive. Obviously, 1.75 mmol/L calcium dial-
ysate could be indicated in some particular patients, but 
not in a generalized form. 
The last comment is on 25(OH) vitamin D levels. In "Pa-
tients and Methods" the authors report they measured 
calcidiol every six months, but nothing is referred in the 
results or in the logistic regression analysis. This could be 
an interesting point to add for further investigation in or-
der to explain secondary hyperparathyroidism.
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